Search Result

Results for "

synuclein-

" in MedChemExpress (MCE) Product Catalog:

By Targets:	α-synuclein (110) Amino Acid Derivatives (1) AMPK (1) Amylin Receptor (2) Amyloid-β (15) Apoptosis (24) Atg8/LC3 (1) Autophagy (18) Bcl-2 Family (9) Bcr-Abl (1) Beclin1 (1) Caspase (3) CGRP Receptor (1) Claudin (1) DNA/RNA Synthesis (3) Dopamine Receptor (2) Drug Derivative (1) Drug Metabolite (8) DYRK (3) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (3) Environmental Pollutants (3) Fluorescent Dye (2) Fungal (3) GLP Receptor (8) Glycosidase (1) GSK-3 (1) Huntingtin (1) IKK (1) Insulin Receptor (8) Interleukin Related (2) Isotope-Labeled Compounds (11) JNK (1) Keap1-Nrf2 (1) LRRK2 (1) Microtubule/Tubulin (1) Mitosis (3) Monoamine Oxidase (4) Natriuretic Peptide Receptor (NPR) (1) Necroptosis (1) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) Nuclear Hormone Receptor 4A/NR4A (1) OGA (1) P-glycoprotein (5) p38 MAPK (9) Parasite (2) PI3K (1) PROTACs (3) Proteasome (1) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (2) Reactive Oxygen Species (ROS) (4) Reference Standards (10) RIP kinase (1) Sirtuin (1) SOD (1) Succinate Dehydrogenase (1) Tau Protein (5) Transthyretin (TTR) (1) Tyrosine Hydroxylase (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (3) Infection (5) Inflammation/Immunology (13) Metabolic Disease (14) Neurological Disease (136)
Oligonucleotides:	Antisense Oligonucleotides (2)

144

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: α-synuclein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101855

Emrusolmin Anle138b	Amyloid-β	Neurological Disease
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-P99405

Prasinezumab PRX 002; RG 7935; RO 7046015	α-synuclein	Neurological Disease
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated *α-synuclein*. Prasinezumab has the potential for Parkinson's disease research .

HY-121252

Dopal	α-synuclein Apoptosis Drug Metabolite	Neurological Disease
Dopal is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal exhibits cytotoxicity, induces *α-synuclein* oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal can be used in research related to Parkinson's disease .

HY-N1501

Beta-asarone 4 Publications Verification	α-synuclein	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

HY-107811

Harmol 1 Publications Verification	Autophagy α-synuclein Apoptosis Monoamine Oxidase Mitosis	Neurological Disease Cancer
Harmol is an orally active β-carboline alkaloid. Harmol is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of *α-synuclein* by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

HY-160116

*α-Synuclein* aggregate binder 1**	Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for *α-synuclein* aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with ¹⁸F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .

HY-N0743

Senkyunolide A 4 Publications Verification	α-synuclein	Neurological Disease Inflammation/Immunology Cancer
Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and *α-synuclein* phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis .

HY-16009

Buntanetap (+)-Phenserine; ANVS401	α-synuclein	Neurological Disease Inflammation/Immunology
Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .

HY-157839

*PROTAC α-Synuclein/Tau degrader 1*	PROTACs α-synuclein Tau Protein	Neurological Disease
PROTAC α-Synuclein/Tau degrader 1 is a blood-brain barrier-penetrant dual PROTAC degrader of α-synuclein (α-Syn) and tau, with DC₅₀ of 1.57 μM and 4.09 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 binds to α-Syn and tau PFF, with K_Ds of 0.47 and 2.78 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 exhibits degradation effect mediated by the ubiquitin-proteasome system (UPS). PROTAC α-Synuclein/Tau degrader 6 can be used for the study of Parkinson’s disease (PD) (Pink: α-Synuclein/Tau ligand (HY-151035); Blue: CRBN ligase ligand (HY-14658); Black: Linker (HY-128803)) .

HY-P99356

Cinpanemab BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)	α-synuclein	Neurological Disease
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to *α-synuclein*. Cinpanemab can be used for the research of Parkinson's disease .

HY-120475

PBT434 2 Publications Verification ATH434	α-synuclein	Neurological Disease
PBT434 is a potent, orally active and cross the blood-brain barrier *α-synuclein* aggregation** inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .

HY-N0698

Crocin II	Endogenous Metabolite α-synuclein	Neurological Disease Cancer
Crocin II is an inhibitor targeting *α-synuclein* aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits *α-synuclein* aggregation and dissociates pre-formed *α-synuclein* fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers .

HY-135902A

Synucleozid hydrochloride 2 Publications Verification NSC 377363 hydrochloride	DNA/RNA Synthesis	Neurological Disease
Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the?SNCA?mRNA?that encodes α-synuclein protein. Synucleozid selectively?targets the?α-synuclein?mRNA 5′ UTR at the designed IRE site, decreases the amount of?SNCA?mRNA loaded into polysomes and thereby inhibits?SNCA?translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-N0901

Corynoxine 3 Publications Verification	Autophagy	Neurological Disease Cancer
Corynoxine, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria rhynchophylla. Corynoxine is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

HY-124876

SynuClean-D 1 Publications Verification SC-D	α-synuclein	Neurological Disease
SynuClean-D (SC-D) is an inhibitor of *α-synuclein* aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .

HY-175748

MK-7337	Radionuclide-Drug Conjugates (RDCs) α-synuclein	Neurological Disease
MK-7337 is an *α-synuclein* ligand with an affinity of < 1 nM. MK-7337 labeled with ¹¹C can be used as a PET tracer for neurodegenerative disorders like Parkinson’s disease imagination .

HY-W042156

Aegeline	Fungal	Neurological Disease
Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .

HY-122958

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an *α-synuclein* fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease .

HY-155021

*PROTAC α-synuclein* degrader 5**	PROTACs α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 5 is a highly selective small-molecule degrader (PROTAC) of *α-synuclein* aggregates, with a DC₅₀ of 7.51 μM and the highest degradation rate D_max of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research .

HY-N0901A

Corynoxine B 5 Publications Verification	α-synuclein	Neurological Disease Cancer
Corynoxine B is an alkaloid-based autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .

HY-156585

CNS-11	Tau Protein α-synuclein	Neurological Disease
CNS-11 is a brain-penetrant tau fibril-degrading compound. CNS-11 reduces *α-synuclein*. CNS-11 can be used in Alzheimer's and Parkinson's disease research .

HY-D1443

BSB (trans,trans)-1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene	Amyloid-β	Others
BSB is a Congo red-derived fluorescent probe. BSB binds not only to extracellular amyloid β protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins. BSB acts as a prototype imaging agent for Alzheimer's disease .

HY-155659

4A7C-301 1 Publications Verification	Nuclear Hormone Receptor 4A/NR4A	Neurological Disease
4A7C-301 is a Nurr1 agonist with robust neuroprotective effects in vitro. 4A7C-301 significantly ameliorates neuropathological abnormalities and improves motor and olfactory dysfunctions in AAV2-mediated α-synuclein-overexpressing male mouse models. 4A7C-301 can be used for the research of Parkinson’s disease .

HY-156586

Egalognastat ASN90	OGA Tau Protein	Neurological Disease
Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC₅₀ value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .

HY-136001

*PROTAC α-synuclein* degrader 3**	PROTACs α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 3 (Compound 5) is a selective *α-synuclein* PROTAC degrader. PROTAC α-synuclein degrader 3 can promote the ubiquitination and degradation of α-synuclein. PROTAC α-synuclein degrader 3 can be used for Parkinson's disease research (Pink: target protein ligand (HY-W278021); Black: linker; HY-133302; Blue: E3 ligase VHL ligand (HY-112078)) .

HY-120475A

PBT434 mesylate 2 Publications Verification ATH434 mesylate	α-synuclein	Neurological Disease
PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier *α-synuclein* aggregation** inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .

HY-125287

(Rac)-Minzasolmin (Rac)-UCB0599; NPT200-11	α-synuclein	Neurological Disease
(Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) .

HY-120034

NCGC 607 1 Publications Verification	Glycosidase α-synuclein	Neurological Disease Metabolic Disease
NCGC 607 is a noninhibitory small-molecule chaperone of glucocerebrosidase (GCase). NCGC 607 can increase GCase activity, reduce *α-synuclein* levels, and decrease glycolipid levels. NCGC 607 can be used in the research of Gaucher disease and Parkinson's disease .

HY-N0413

Hupehenine	α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite	Infection Neurological Disease Inflammation/Immunology Cancer
Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .

HY-P5082

*α-Synuclein* 4554W**	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-145580A

(S)-Minzasolmin (S)-UCB0599; (S)-NPT200-11	α-synuclein	Neurological Disease
(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

HY-150209

MODAG-001	Fluorescent Dye	Neurological Disease
MODAG-001 can bind to synuclein fibrils in a rat brain. MODAG-001 is a candidate α-syn imaging probe .

HY-401209

Synucleozid-2.0	α-synuclein DNA/RNA Synthesis	Neurological Disease
Synucleozid-2.0 is a blood-brain barrier-permeable inhibitor that binds to the IRE of SNCA mRNA, with a EC₅₀ of 2.9 µM and a K_d value of 1.8 µM. Synucleozid-2.0 selectively binds to and stabilizes the A bulge and adjacent closed base pairs in the 5' UTR IRE of SNCA mRNA, blocks the translation process and reduces intracellular levels of *α-synuclein. Synucleozid-2.0 exerts cytoprotective effects against cytotoxicity induced by α-synuclein* preformed fibrils. Synucleozid-2.0 is applicable to the research of Parkinson's disease .

HY-110174

NAB2	α-synuclein	Neurological Disease
NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from *α-synuclein* toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease .

HY-W049881

9-Methyl-β-carboline	Dopamine Receptor PI3K Monoamine Oxidase	Neurological Disease
9-Methyl-β-carboline is a monoamine oxidase inhibitor and dopaminergic modulator, with an IC₅₀ of 1 μM against human MAO-A and an IC₅₀ of 15.5 μM against human MAO-B. 9-Methyl-β-carboline possesses cognitive enhancement potential and can cross the blood-brain barrier. 9-Methyl-β-carboline increases dopamine levels by inhibiting monoamine oxidase activity and microglial proliferation. 9-Methyl-β-carboline activates PKA/PKC and mitochondrial respiratory chain complex I, promotes neurotrophic factor expression and reduces α-synuclein (α-synuclein) levels, thereby reversing neurotoxin-induced dopaminergic neuron damage. 9-Methyl-β-carboline also regulates the PI3K pathway and exerts an anti-proliferative effect on astrocytes. 9-Methyl-β-carboline is widely used in Parkinson's disease-related studies .

HY-P3140A

*α-Synuclein* (61-75) TFA**	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P4704A

*α-Synuclein* (61-95) (human) TFA**	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-157308

*α-Synuclein* inhibitor 10**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

HY-135902

Synucleozid NSC 377363	DNA/RNA Synthesis	Neurological Disease
Synucleozid (NSC 377363) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the *α-synuclein* mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-P3140

*α-Synuclein* (61-75)**	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-178920

*α-Synuclein-IN-17*	α-synuclein	Neurological Disease
α-Synuclein-IN-17 (Compound 10) is an *α-Synuclein* inhibitor, with an IC₅₀ value of 9 μM. α-Synuclein-IN-17 exhibits potent inhibitory activity against both in-vitro assembled asyn fibrils and LBD brain tissue-amplified asyn fibrils. α-Synuclein-IN-17 can be used for the study of Parkinson's disease (PD) and Lewy Body Disease (LBD) .

HY-163145

*α-Synuclein* inhibitor 11**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 11 (compound 1) is a selective *α-synuclein* (α-syn) oligomer formation** inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .

HY-P10360

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an *α-synuclein* knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .

HY-177647

Movronersen BIIB-101; ION-464	α-synuclein	Neurological Disease
Movronersen is an antisense oligonucleotide targeted to α-synuclein.

HY-115038

ELN484228	α-synuclein	Neurological Disease
ELN484228 is a blocker of *α-synuclein* which is a key protein in Parkinson’s disease.

HY-153416

QR-0217	Amyloid-β	Neurological Disease
QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC₅₀ value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .

HY-121252A

Dopal (purity>80%)	α-synuclein Apoptosis Drug Metabolite	Neurological Disease
Dopal (purity>80%) is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal (purity>80%) exhibits cytotoxicity, induces *α-synuclein* oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal (purity>80%) can be used in research related to Parkinson's disease .

HY-175737

*α-synuclein-IN-16*	α-synuclein	Neurological Disease
α-synuclein-IN-16 (Compound H1) is a *α-synuclein* inhibitor. α-synuclein-IN-16 significantly inhibits the secondary nucleation in α-synuclein aggregation. α-synuclein-IN-16 can be used for Parkinson’s disease research .

HY-P5043

*α-Synuclein* (67-78) (human)**	α-synuclein	Neurological Disease
α-Synuclein (67-78) (human) is the 67-78 fragment of *α-Synuclein. α-Synuclein* (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake .

HY-N15613

*α-Synuclein* inhibitor 14**	α-synuclein	Neurological Disease
α-Synuclein inhibitor 14 (Compound 3) is a diarylheptanoid that can be isolated from Alpinia officinarum. α-Synuclein inhibitor 14 can inhibit the aggregation of *α-synuclein, with an inhibition rate of 72.4% at a concentration of 10 μM. α-Synuclein* inhibitor 14 can be used in the research of neurodegenerative diseases such as Parkinson's disease .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library

2,046 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 2,046 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Cat. No.	Product Name	Type

HY-D0914

Fast Green FCF

FD&C Green No. 3; Food green 3; C.I. 42053

Fluorescent Dye

Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-D1443

BSB (trans,trans)-1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene	Fluorescent Dye
BSB is a Congo red-derived fluorescent probe. BSB binds not only to extracellular amyloid β protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins. BSB acts as a prototype imaging agent for Alzheimer's disease .

HY-D0914A

Fast green FCF free acid

Fluorescent Dye

Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Cat. No.	Product Name	Target	Research Area

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P5082

*α-Synuclein* 4554W**	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-P3140A

*α-Synuclein* (61-75) TFA**	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P4704A

*α-Synuclein* (61-95) (human) TFA**	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3140

*α-Synuclein* (61-75)**	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P10360

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an *α-synuclein* knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .

HY-P5043

*α-Synuclein* (67-78) (human)**	α-synuclein	Neurological Disease
α-Synuclein (67-78) (human) is the 67-78 fragment of *α-Synuclein. α-Synuclein* (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake .

HY-P4704

*α-Synuclein* (61-95) (human)**	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P5044

*α-Synuclein* (45-54) (human)**	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5041

*α-Synuclein* (34-45) (human)**	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P5046

*α-Synuclein* (71-82) (human)**	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
PDpep1.3 is a peptide inhibitor of *α-synuclein* that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .

HY-P10844

ANK peptide	Amino Acid Derivatives	Cancer
ANK peptide is a novel peptide designed based on the conserved residues of single ankyrin motif. ANK peptide is a synuclein-γ (SNCG) inhibitor that binds to SNCG and competes with SNCG-BubR1 interaction to enhance the sensitivity of breast cancer cells to antimicrotubule drugs such as nocodazole and paclitaxel. ANK peptide can be used in the study of cancer .

HY-P5106

*α-Synuclein* (32-37) (human)**	Peptides	Others
α-Synuclein (32-37) (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P11581

MNP2	NOD-like Receptor (NLR) Interleukin Related Caspase Amyloid-β Tau Protein α-synuclein Pyroptosis	Neurological Disease
MNP2 is a NLRP3-ASC interaction inhibitor. MNP2 selectively binds to the PYD domain of ASC (K_a=149 nM) and blocks ASC-PYM binding (K_a=58 nM), thereby inhibiting the interaction between ASC and NLRP3 and suppressing the formation of the NLRP3 inflammasome. MNP2 inhibits IL-1β release and caspase-1 maturation, and reduces the efflux of potassium and chloride ions. MNP2 prevents mitochondrial damage and reactive oxygen species production, and significantly decreases NLRP3 inflammasome formation in neurodegenerative pathologies induced by β-amyloid, Tau protein and *α-synuclein*. MNP2 is applicable for the research of neurodegenerative diseases .

HY-114118C

Semaglutide sodium	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing *α-synuclein* aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99405

Prasinezumab PRX 002; RG 7935; RO 7046015	α-synuclein	Neurological Disease
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated *α-synuclein*. Prasinezumab has the potential for Parkinson's disease research .

HY-P99356

Cinpanemab BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)	α-synuclein	Neurological Disease
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to *α-synuclein*. Cinpanemab can be used for the research of Parkinson's disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-153169

6PPD-Q Maximum Cited Publications 7 Publications Verification 6PPD-Quinone	Quinones Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Other Diseases Benzene Quinones Endogenous metabolite Disease Research Fields Source Classification	α-synuclein Environmental Pollutants
6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders .

HY-121252

Dopal	Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	α-synuclein Apoptosis Drug Metabolite
Dopal is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal exhibits cytotoxicity, induces *α-synuclein* oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal can be used in research related to Parkinson's disease .

HY-N1501

Beta-asarone 4 Publications Verification	Acorus tatarinowii Schott Simple Phenylpropanols Araceae Phenylpropanoids Plants Source Classification	α-synuclein
Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

HY-107811

Harmol 1 Publications Verification	Neurological Disease Classification of Application Fields Peganum harmala Linn. Pyridine Alkaloids Plants Endogenous metabolite Indole Alkaloids Alkaloids Monophenols Zygophyllaceae Phenols Disease Research Fields Source Classification	Autophagy α-synuclein Apoptosis Monoamine Oxidase Mitosis
Harmol is an orally active β-carboline alkaloid. Harmol is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of *α-synuclein* by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

HY-113283

Homogentisic acid	Structural Classification Other disease Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields	Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as *Aβ_1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin* pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .

HY-N0743

Senkyunolide A 4 Publications Verification	Natural Products Classification of Application Fields Dicerothamnus rhinocerotis Umbelliferae Plants Disease Research Fields Source Classification Cancer	α-synuclein
Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and *α-synuclein* phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis .

HY-N2099

Onjisaponin B 2 Publications Verification Senegin III	Triterpenes Structural Classification Neurological Disease Classification of Application Fields Terpenoids Polygalaceae Plants Polygala tenuifolia Willd. Disease Research Fields Source Classification	Autophagy Amyloid-β Caspase NF-κB Apoptosis
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-Y0790

Cuminaldehyde 1 Publications Verification p-Isopropylbenzaldehyde	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Rudbeckia laciniata L. Umbelliferae Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	Environmental Pollutants α-synuclein
Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL), α-glucosidase (IC₅₀=0.5 mg/mL) and lipoxygenase (IC₅₀=1370 μM). Cuminaldehyde also inhibits the fibrillation of *α-synuclein* and prevents its aggregation. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-W010041

Scyllo-Inositol	Natural Products Endogenous metabolite Source Classification	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as *α-synuclein* and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N0698

Crocin II	Structural Classification Neurological Disease Classification of Application Fields Terpenoids Rubiaceae Diterpenoids Plants Gardenia jasminoides Ellis Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite α-synuclein
Crocin II is an inhibitor targeting *α-synuclein* aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits *α-synuclein* aggregation and dissociates pre-formed *α-synuclein* fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers .

HY-N0901

Corynoxine 3 Publications Verification	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Rubiaceae Plants Indole Alkaloids Source Classification	Autophagy
Corynoxine, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria rhynchophylla. Corynoxine is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

HY-W042156

Aegeline	Alkaloids Other Alkaloids Rutaceae Plants Aegle marmelos (L.) Correa Source Classification	Fungal
Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .

HY-122958

Peucedanocoumarin III	Structural Classification Carpesium cernuum L. Coumarins Phenylpropanoids Umbelliferae Plants Source Classification	α-synuclein
Peucedanocoumarin III is an *α-synuclein* fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease .

HY-N0901A

Corynoxine B 5 Publications Verification	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Classification of Application Fields Rubiaceae Plants Disease Research Fields Indole Alkaloids Source Classification Cancer	α-synuclein
Corynoxine B is an alkaloid-based autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .

HY-N0413

Hupehenine	Alkaloids Liliaceae Classification of Application Fields Fritillaria hupehensis Hsiao et K. C. Hsia Plants Inflammation/Immunology Disease Research Fields Indole Alkaloids Source Classification	α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite
Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .

HY-N1501R

Beta-asarone (Standard)	Acorus tatarinowii Schott Structural Classification Simple Phenylpropanols Araceae Phenylpropanoids Plants Source Classification	α-synuclein Reference Standards
Beta-asarone (Standard) is the analytical standard of Beta-asarone. This product is intended for research and analytical applications. Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

HY-N15613

*α-Synuclein* inhibitor 14**	Phenols Polyphenols Plants Tacca chantrieri Andre Taccaceae Source Classification	α-synuclein
α-Synuclein inhibitor 14 (Compound 3) is a diarylheptanoid that can be isolated from Alpinia officinarum. α-Synuclein inhibitor 14 can inhibit the aggregation of *α-synuclein, with an inhibition rate of 72.4% at a concentration of 10 μM. α-Synuclein* inhibitor 14 can be used in the research of neurodegenerative diseases such as Parkinson's disease .

HY-N10306

Sycosterol A	Animals Steroids Source Classification	α-synuclein
Sycosterol A is a sterol-based *α-synuclein* (α-syn)** inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases .

HY-N16524

Alpinin A	Structural Classification Phenols Polyphenols Alpinia officinarum Hance Plants Source Classification Zingiberaceae	α-synuclein
Alpinin A is a diarylheptanoid found in the rhizomes of Alpinia officinarum. Alpinin A can strongly inhibit the aggregation of *α-synuclein* with inhibition rate of 66% at 10 μM. Alpinin A can be used for the research of neurological disease, such as Parkinson’s disease .

HY-N2099A

(Z)-Onjisaponin B (Z)-Senegin III	Triterpenes Structural Classification Polygala senega L. Terpenoids Polygalaceae Plants Pentacyclic Triterpenoids Source Classification	Drug Derivative
(Z)-Onjisaponin B ((Z)-Senegin III) is a derivative of Onjisaponin B (HY-N2099). Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-Y0790R

Cuminaldehyde (Standard) p-Isopropylbenzaldehyde (Standard)	Structural Classification Ketones, Aldehydes, Acids Rudbeckia laciniata L. Umbelliferae Plants Endogenous metabolite Source Classification	α-synuclein Reference Standards
Cuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL) and α-glucosidase (IC₅₀=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of *α-synuclein* and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-130398

Aerophobin-2	Natural Products Marine natural products Sponge Source Classification	α-synuclein
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-N0698R

Crocin II (Standard)	Structural Classification Terpenoids Rubiaceae Diterpenoids Plants Gardenia jasminoides Ellis Source Classification	Reference Standards Endogenous Metabolite α-synuclein
Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting *α-synuclein* aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits *α-synuclein* aggregation and dissociates pre-formed *α-synuclein* fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.

HY-N0901AR

Corynoxine B (Standard)	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Structural Classification Rubiaceae Plants Indole Alkaloids Source Classification	α-synuclein Reference Standards
Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice .

HY-N0901B

Corynoxine hydrochloride	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Rubiaceae Plants Indole Alkaloids Source Classification	Autophagy
Corynoxine hydrochloride, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria macrophylla. Corynoxine hydrochloride is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

HY-W042156R

Aegeline (Standard)	Alkaloids Structural Classification Other Alkaloids Rutaceae Plants Aegle marmelos (L.) Correa Source Classification	Reference Standards Fungal
Aegeline (Standard) is the analytical standard of Aegeline. This product is intended for research and analytical applications. Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .

HY-N0413R

Hupehenine (Standard)	Alkaloids Structural Classification Liliaceae Fritillaria hupehensis Hsiao et K. C. Hsia Plants Indole Alkaloids Source Classification	Reference Standards α-synuclein Reactive Oxygen Species (ROS) Apoptosis Autophagy Parasite
Hupehenine (Standard) is the analytical standard of Hupehenine (HY-N0413). This product is intended for research and analytical applications. Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders .

HY-107811R

Harmol (Standard)	Alkaloids Monophenols Zygophyllaceae Peganum harmala Linn. Phenols Pyridine Alkaloids Plants Endogenous metabolite Indole Alkaloids Source Classification	Apoptosis Monoamine Oxidase Autophagy α-synuclein Mitosis Reference Standards
Harmol (Standard) is the analytical standard of Harmol (HY-107811). This product is intended for research and analytical applications. Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of *α-synuclein* by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

HY-W010041R

Scyllo-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N17816

Tambulin	Structural Classification Flavonoids Flavones Rutaceae Plants Zanthoxylum armatum DC. Source Classification	Apoptosis Reactive Oxygen Species (ROS) α-synuclein Succinate Dehydrogenase Bcl-2 Family Caspase
Tambulin is an orally active flavonol compound found in Zanthoxylum armatum. Tambulin can inhibit cell proliferation, induce apoptosis and inhibit ROS production. Tambulin upregulates cleaved caspase-3, cleaved caspase-9, and Bax, downregulates Bcl-2 levels. Tambulin can stimulate glucose-dependent insulin secretion and induce endothelium-independent vasorelaxation. Tambulin binds to succinate dehydrogenase (SDH) (Ki = 11.02 μM) and shows significant ferric reducing power. Tambulin can enhances oxidative stress resistance, reduces, lipofuscin deposits, lipid levels, *α-synuclein* levels, improves locomotary behavior, and dopamine levels in in age-synchronized L1 hermaphrodite Caenorhabditis elegans models of ageing and Parkinson's disease. Tambulin can be used for the researches of Parkinson's disease, lung squamous cell carcinoma, and diabetes .

Species:	Human (12) Mouse (2) Cynomolgus (1)
Tag:	His (8) Tag Free (6) Avi (1) Fc (1)
Source:	HEK293 (2) E. coli (13)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702985

	SNCB Protein, Human (His) Beta-synuclein; SNCB	Human	E. coli
	SNCB Protein, Human (His) is the recombinant human-derived SNCB, expressed by E. coli , with His labeled tag. ,

HY-P705391

	SNCA Protein, Cynomolgus (His) Alpha-synuclein; SNCA	Cynomolgus	E. coli

HY-P78805

	SNCA Protein, Human (Biotinylated, HEK293, His-Avi) SNCA; NACP; PARK1; alpha-synuclein	Human	HEK293
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SNCA protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P70660

	SNCA Protein, Mouse Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca	Mouse	E. coli
	SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA Protein, Mouse is the recombinant mouse-derived SNCA protein, expressed by E. coli , with tag free.

HY-P71043

	SNCG Protein, Human Gamma-synuclein; Breast Cancer-Specific Gene 1 Protein; Persyn; Synoretin; SR; SNCG; BCSG1; PERSYN; PRSN	Human	E. coli
	SNCG proteins help maintain the integrity of neurofilament networks and may influence axonal structure during development and adulthood. In vitro, it enhances the sensitivity of neurofilament-H to calcium-dependent proteases. SNCG Protein, Human is the recombinant human-derived SNCG protein, expressed by E. coli , with tag free.

HY-P704896

	SNCA Protein, Mouse (His) Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca	Mouse	E. coli

HY-P70577

	SNCA Protein, Human 2 Publications Verification Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	SNCA Protein is a protein abnormally aggregated to form Lewy bodies. SNCA Protein causes neuronal differentiation and maturation disorders, inhibits neurite outgrowth, reduces neuronal electrical activity through increased gene copy number (such as triploidy) or mutation, and promotes the release of extracellular toxic particles (such as oligomers) by interfering with the autophagy-lysosomal pathway (ALP), thereby inducing inflammatory responses and damage to neighboring cells. SNCA Protein, Human is a recombinant SNCA protein expressed by E. coli without a tag.

HY-P71327

	SNCA Protein, Human (His) 1 Publications Verification Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (His) is the recombinant human-derived SNCA protein, expressed by E. coli , with N-6*His labeled tag.

HY-P704889

	SNCA Protein, Human (HEK293, Fc) Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	HEK293

HY-P704891

	SNCA Protein, Human (A53T) Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704892

	SNCA Protein, Human (E46K) Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704894

	SNCA Pre-formed Fibrils Protein, Human Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704890

	SNCA Protein, Human (A53T, His) Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704893

	SNCA Pre-formed Fibrils Protein, Human (His) Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

HY-P704895

	SNCA Pre-formed Fibrils Protein, Human (A53T, His) Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-G0017S

N-Desmethyl imatinib-d8

N-Desmethyl imatinib-d₈ is a deuterium labeled Imatinib metabolite N-Desmethyl Imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .

HY-176306S

Synuclein alpha, Lys-13C6,15N2
Synuclein alpha, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C-labeled and ¹⁵N-labeled Synuclein alpha.

HY-Y0790S

Cuminaldehyde-d8
Cuminaldehyde-d8 is deuterated labeled Cuminaldehyde (HY-Y0790). Cuminaldehyde is the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on alpha-synuclein fibrillation and cytotoxicity. Cuminaldehyde shows anticancer activity .

HY-121252S

Dopal-d5
Dopal-d₅ is the deuterium labeled Dopal (HY-121252). Dopal is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal exhibits cytotoxicity, induces *α-synuclein* oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal can be used in research related to Parkinson's disease .

HY-W707693

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-G0017S1

N-Desmethyl imatinib-d4

N-Desmethyl imatinib-d₄ is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .

HY-176308S

Synuclein gamma, U-15N
Synuclein gamma, U- ¹⁵N is the ¹⁵N-labeled Synuclein gamma.

HY-176307S

Synuclein beta, U-15N
Synuclein beta, U- ¹⁵N is the ¹⁵N-labeled Synuclein beta.

Host:	Mouse (3) Rabbit (10)
Reactivity:	Human (13) Rat (10) Mouse (6)
Application:	IHC-P (9) ICC/IF (7) IF-Tissue (5) IP (6) IHC-F (4) WB (12) FC (4) ELISA (2)
Isotype:	IgG, Kappa (1) IgG (12)
Conjugation:	Non-conjugated (13) Biotin (1)
Clonality:	Monoclonal (11) Recombinant (7)
Modification:	Phosphorylated (2) Unmodified (9)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83254

	*alpha/beta Synuclein* Antibody (YA2999)** alpha synuclein; beta synuclein; NACP; PD1; SNCA; SNCB	WB, ICC/IF, FC	Human, Mouse, Rat
	alpha/beta Synuclein Antibody (YA2999) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha/beta Synuclein.

HY-P81612

	*gamma Synuclein/SNCG Antibody (YA1357)* BCSG1; Breast cancer specific gene 1 protein; Gamma synuclein; Persyn; PRSN; SNCG; SR; Synoretin; synuclein gamma	WB, IHC-P, ICC/IF, IP, FC	Human, Rat
	gamma Synuclein/SNCG Antibody (YA1357) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to gamma Synuclein/SNCG.

HY-P87290

	*alpha+beta Synuclein* Antibody (YA6973)** Alpha synuclein antibody; Beta synuclein antibody; NACP antibody; Non A beta component of AD amyloid antibody; PARK1 antibody; PARK4 antibody; PD1 antibody; SNCA antibody; SNCB antibody; synuclein alpha antibody	WB, ICC/IF, IF-Tissue, IHC-P, FC	Human, Mouse, Rat
	alpha+beta Synuclein Antibody (YA6973) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha+beta Synuclein.

HY-P87749

	*Phospho-Synuclein-α (Ser129) Antibody (YA7434)*	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Phospho-Synuclein-α (Ser129) Antibody (YA7434) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-Synuclein-α (Ser129).

HY-P85381

	*gamma Synuclein/SNCG Antibody (YA5073)* SNCG; BCSG1; PERSYN; PRSN; Gamma-synuclein; Breast cancer-specific gene 1 protein; Persyn; Synoretin; SR	WB, IHC-P, IHC-F, ICC/IF, IF-Tissue, IP, FC	Human, Rat
	gamma Synuclein/SNCG Antibody (YA5073) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to gamma Synuclein/SNCG.

HY-P86701

	*alpha Synuclein* Antibody (YA6393)** SNCA; SYUA_HUMAN; alpha synuclein; alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid, precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease(autosomal dominant, Lewy body) 4; Parkinson disease familial 1; Syn; Snca synuclein, alpha(non A4 component of amyloid precursor); synuclein alpha; synuclein, alpha(non A4 component of amyloid precursor); synuclein-α; synuclein α.	WB	Rat, Mouse, Human
	alpha Synuclein Antibody (YA6393) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

HY-P86749

	*alpha Synuclein* Antibody (YA6441)** SNCA; SYUA_HUMAN; alpha synuclein; alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid, precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease(autosomal dominant, Lewy body) 4; Parkinson disease familial 1; Syn; Snca synuclein, alpha(non A4 component of amyloid precursor); synuclein alpha; synuclein, alpha(non A4 component of amyloid precursor); synuclein-α; synuclein α.	WB, IHC-P, IHC-F, IF-Tissue	Human
	alpha Synuclein Antibody (YA6441) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

HY-P86749A

	*alpha Synuclein* Antibody (YA6441)(PBS only)** SNCA; SYUA_HUMAN; alpha synuclein; alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid, precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease(autosomal dominant, Lewy body) 4; Parkinson disease familial 1; Syn; Snca synuclein, alpha(non A4 component of amyloid precursor); synuclein alpha; synuclein, alpha(non A4 component of amyloid precursor); synuclein-α; synuclein α.	WB, IHC-P, IHC-F, IF-Tissue	Human
	alpha Synuclein Antibody (YA6441) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

HY-P82328

	*alpha Synuclein* Antibody (YA2073)** 1 Publications Verification SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, IHC-P, IP	Human, Rat
	alpha Synuclein Antibody (YA2073) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

HY-P85380

	*alpha Synuclein* Antibody (YA5072)** SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	IHC-P, IHC-F, IF-Tissue	Human
	alpha Synuclein Antibody (YA5072) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to alpha Synuclein.

HY-P86127

	*alpha Synuclein* Antibody (YA5819)** SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	alpha Synuclein Antibody (YA5819) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

HY-P82328A

	*alpha Synuclein* Antibody (YA2073)(PBS only)** SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, IHC-P, IP	Human, Rat
	alpha Synuclein Antibody (YA2073) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

HY-P81739

	*Phospho-alpha Synuclein* (Ser129) Antibody (YA1484)** SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, ICC/IF	Human, Mouse, Rat
	Phospho-alpha Synuclein (Ser129) Antibody (YA1484) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-alpha Synuclein (Ser129).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

synuclein-

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products